Faculty

Back to Index
Shannon M Mumenthaler, PhD
Assistant Professor of Medicine
Medicine
CSC 240 Off Campus Los Angeles
+1 323 442 2529

Overview

Dr. Mumenthaler is an Assistant Professor of Research Medicine at the CAMM. She received a B.S. in Genetics from UC Davis and a Ph.D. in Cellular and Molecular Pathology from UCLA. Although her primary scientific training is in cell biology, Dr. Mumenthaler applies a unique multidisciplinary approach toward her research program, partnering with mathematicians, clinicians, and engineers to explore critical areas in cancer. Her current research interests focus on the development of tools to better understand the evolutionary dynamics of tumor progression and drug resistance with specific investigations into the influence of microenvironmental selective pressures on tumor cell behavior. Toward this goal, Dr. Mumenthaler is closely collaborating with mathematical modelers to combine novel computational platforms with diverse experimental measurements to test and refine biological hypotheses and make clinically relevant predictions.

Awards

National Cancer Institute: Junior Investigator Award, 2013

USC: Medical Faculty Women's Association Award, 2013

Third Annual National Cancer Institute Physical Sciences in Oncology Center: Best Poster Award, 2012

University of California, Los Angeles: Hortenese Fishbaugh Memorial Scholarship, 2006-2007

University of California, Los Angeles: Life Sciences Core Curriculum Teaching Assistant Honorarium Award, 2005-2006

University of California, Davis: Graduated with Honors, 2003

University of California, Davis: Undergraduate Student of the Year Award, Division of Biological Sciences, 2003

University of California, Davis: Howard Hughes Medical Institute Summer Honors Advanced Research Program (SHARP) Fellowship, 2002

University of California, Davis: Alumni Scholarship, 2000

Webber Foundation: Academic Scholarship, 1999-2003

Publications

Dual transcript and protein quantification in a massive single cell array. Lab Chip. 2016 Oct 7; 16(19):3682-8. View in: PubMed

Single cell dynamic phenotyping. Sci Rep. 2016 Oct 06; 6:34785. View in: PubMed

Quantifying differences in cell line population dynamics using CellPD. BMC Syst Biol. 2016 Sep 21; 10(1):92. View in: PubMed

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. PLoS Comput Biol. 2016 Aug; 12(8):e1005077. View in: PubMed

Significance of duon mutations in cancer genomes. Sci Rep. 2016; 6:27437. View in: PubMed

Progress Towards Computational 3-D Multicellular Systems Biology. Adv Exp Med Biol. 2016; 936:225-246. View in: PubMed

A high-content image-based method for quantitatively studying context-dependent cell population dynamics. Sci Rep. 2016; 6:29752. View in: PubMed

Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance. Biomarkers. 2015 Jul; 20(5):313-22. View in: PubMed

Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS One. 2015; 10(6):e0129433. View in: PubMed

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31. View in: PubMed

Anti-MET ImmunoPET for Non-Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Mol Cancer Ther. 2014 Nov; 13(11):2607-17. View in: PubMed

The Need for Integrative Computational Oncology: An Illustrated Example through MMP-Mediated Tissue Degradation. Front Oncol. 2013; 3:194. View in: PubMed

Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumors. Evol Appl. 2013 Jan; 6(1):54-69. View in: PubMed

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449. View in: PubMed

Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 5; 8(6):2069-79. View in: PubMed

Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93. View in: PubMed

17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice. J Cardiovasc Transl Res. 2009 Sep; 2(3):289-99. View in: PubMed

CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology. 2009 Apr 25; 387(1):59-66. View in: PubMed

Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate. 2008 Oct 1; 68(14):1561-9. View in: PubMed

Expression of arginase II in prostate cancer. Int J Oncol. 2008 Feb; 32(2):357-65. View in: PubMed

Powered bySC CTSI